Recent Articles

Regorafenib Becomes First FDA-Approved Drug for Liver Cancer in Nearly a Decade

| May 24, 2017 | 0 Comments

Regorafenib Becomes First FDA-Approved Drug for Liver Cancer in Nearly a Decade FDA approved the kinase inhibitor regorafenib for some patients with hepatocellular carcinoma, the most common form of liver cancer. See Original Article

Continue Reading

Device Uses Cancer Cells' Mass to Predict Response to Treatment

| May 21, 2017 | 0 Comments

Device Uses Cancer Cells' Mass to Predict Response to Treatment Scientists have designed a device that measures the mass of single cancer cells to predict how cells respond to drug treatment. The technology could potentially help clinicians determine whether a drug effectively kills cancer cells.See Original Article U.S. Cancer Mortality Rates Falling, But Some Regions […]

Continue Reading

Charting a Course toward Precision Cancer Prevention

| May 21, 2017 | 0 Comments

Charting a Course toward Precision Cancer Prevention Cancer researchers are increasingly exploring how cancer risk is influenced by genetic predisposition to cancer and the effects of environmental exposures, and what this means for cancer prevention.See Original Article NCI’s CRCHD Launches National Colorectal Cancer Outreach and Screening Initiative The NCI Center to Reduce Cancer Health Disparities […]

Continue Reading

Mentor Spotlight: Monica L. Baskin, PhD

| May 19, 2017 | 0 Comments

Mentor Spotlight: Monica L. Baskin, PhD Dr. Tiffany Carson, a K01 awardee, recognizes her mentor Dr. Monica Baskin for the guidance and encouragement that she has provided throughout her career.See Original Article

Continue Reading

FDA Grants Brigatinib Accelerated Approval for Metastatic Non-Small Cell Lung Cancer

| May 19, 2017 | 0 Comments

FDA Grants Brigatinib Accelerated Approval for Metastatic Non-Small Cell Lung Cancer On April 28, the FDA granted accelerated approval to the targeted therapy brigatinib (Alunbrig™) for patients with metastatic non-small cell lung cancer (NSCLC) and alterations in the ALK gene whose cancer has progressed during their initial therapy.See Original Article

Continue Reading

Counseling Improves Survivorship Plan Implementation for Low-Income Breast Cancer Survivors

| May 16, 2017 | 0 Comments

Counseling Improves Survivorship Plan Implementation for Low-Income Breast Cancer Survivors In a randomized trial, low-income women who role-played talking with their doctor about their survivorship care plan in a counseling session reported receiving more of their recommended care than women who did not get counseling.See Original Article

Continue Reading

FDA Approves Three Immunotherapy Drugs for Patients with Bladder Cancer

| May 15, 2017 | 0 Comments

FDA Approves Three Immunotherapy Drugs for Patients with Bladder Cancer The FDA has approved three immunotherapy drugs—avelumab, atezolizumab, and durvalumab—for the treatment of patients with bladder cancer. All three drugs belong to a class of cancer therapies known as checkpoint inhibitors.See Original Article

Continue Reading

NCI ALMANAC: A New Tool for Research on Cancer Drug Combinations

| May 12, 2017 | 0 Comments

NCI ALMANAC: A New Tool for Research on Cancer Drug Combinations NCI has released a new, easy-to-use resource called the NCI ALMANAC to help researchers identify potentially promising combinations of cancer drugs. Short description: The resource provides data showing how well pairs of FDA-approved drugs kill tumor cells.See Original Article

Continue Reading

Grantee Spotlight: Manuel L. Penichet, M.D., Ph.D. – Reprogramming the Immune System to Kill Cancer

| May 11, 2017 | 0 Comments

Grantee Spotlight: Manuel L. Penichet, M.D., Ph.D. – Reprogramming the Immune System to Kill Cancer Dr. Manuel L. Penichet, former CURE K01 trainee and NCI R01 grantee, aims to genetically engineer antibodies that can be used to directly target and eliminate cancer cells and also stimulate the body’s immune system to fight and destroy cancer.See […]

Continue Reading

Mentor Spotlight: Elisa V. Bandera, MD, PhD

| May 11, 2017 | 0 Comments

Mentor Spotlight: Elisa V. Bandera, MD, PhD Dr. Brian D. Gonzalez, a K01 awardee, shares how his mentor, Dr. Elisa V. Bandera, has supported his career development. See Original Article Ras Mitogenic Signaling: p53 Enters the Stage Mariano Barbacid and Matthias Drosten describe experiments that reveal a new role for the p53/p21Clp1/Rb axis in controling […]

Continue Reading